ArticleInternational archives of allergy and immunology2025
MicroRNA-4497 Is Downregulated in Pediatric Allergic Diseases and Suppresses Th2 Inflammation in an Animal Model.
Article in International archives of allergy and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in clinical examination techniques for allergic rhinitis: a review from traditional testing to precision diagnosis.Frontiers in allergy · 2026Review
- miRNA-146-a, miRNA-21, miRNA-143, miRNA-29-b and miRNA-223 as Potential Biomarkers for Atopic Dermatitis.Clinics and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Atopic dermatitis (AD), allergic rhinitis (AR), and bronchial asthma (BA) are major allergic diseases in childhood. Pediatric allergic diseases are characterized by the "atopic march," where two or more allergic conditions can occur either simultaneously or sequentially. MicroRNAs (miRNAs) serve as fine regulators of gene expression, capable of modulating the clinical manifestations of allergic diseases posttranscriptionally. We investigated miRNAs commonly expressed in these three allergic diseases to enhance the understanding of their development and management.
methodsWe collected serum samples from subjects diagnosed with AD, AR, and BA as well as from healthy controls at Korea University Anam Hospital. Their miRNA expression patterns were analyzed using microarray technology. Additionally, we examined the allergic inflammatory response of miRNA through an allergic animal model.
resultsA total of 68 subjects were enrolled in the allergy group, consisting of 42 with AD, 13 with AR, and 13 with BA, while 10 children participated as controls. Microarray analysis revealed that miR-4497 expression levels were consistently downregulated in these three allergic disease groups. Following mast cell activation and miR-4497 transfection, reduced levels of macrophage-derived chemokines (MDCs) were observed. Furthermore, levels of IL-4, MDC, and methacholine Penh were significantly decreased in a miR-4497-treated mouse model.
conclusionsMiR-4497 expressions were consistently downregulated in pediatric subjects with AD, AR, and BA. Allergic inflammation was significantly reduced in human mast cell-1 transfected with miR-4497 and in the treated mouse model. Further research is needed to elucidate the epigenetic mechanisms by which miR-4497 modulates allergic diseases and to explore its potential as a noninvasive biomarker for diagnosis and treatment. </p>.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.